OTIVIDEX

Otonomy Inc (NASDAQ: OTIC), a biopharmaceutical company that focuses on therapies related to diseases and disorders of the ear, reported its third-quarter results and announced an encouraging update to a phase 2 trial. What You Need To Know Otonomy lost 69 cents in its third quarter on revenue of...

Shares of Otonomy Inc (NASDAQ: OTIC) plummeted more than 80 percent Wednesday morning after the biopharmaceutical company, which focuses on diseases and disorders of the ear, provided a disappointing update to an ongoing clinical trial. Otonomy has been overseeing a Phase 3 trial called AVERTS-1...